by SH Schmidt 2024With the approval of filgrastim-sndz (Zarxio) and TBO-filgrastim (Granix), drug cost has decreased compared to pegfilgrastim (Neulasta) and filgrastim (
In Skarlos et al, a post-hoc non-randomized subgroup analysis evaluating filgrastim versus pegfilgrastim, a significantly higher incidence of FN was observed in patients treated with pegfilgrastim compared with those receiving filgrastim (13% vs. 1% for pegfilgrastim vs. filgrastim, respectively) .
Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has
Use of pegfilgrastim vs short-acting G-CSF. Clinical trial data suggest a similar efficacy and safety profile with pegfilgrastim and 11 days filgrastim. 1 If 11 days filgrastim is not utilized, pegfilgrastim should be given in preference to a reduced duration of daily filgrastim (consensus reached (91%); evidence level I).
filgrastim (Granix) and sargramostim (Leukine). Filgrastim and pegfilgrastim products are recombinant granulocyte colony- stimulating
Other treatment-related adverse events including arthralgia (1.7 vs 6%), back pain (6.9 vs 3%) and headache (1.7 vs 6%) were reported for pegfilgrastim vs filgrastim.
by P Berto 2024pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Comparison of pegfilgrastim with filgrastim on febrile
Results: Medical records of 624 pts from 34 sites receiving pegfilgrastim or filgrastim have been abstracted to date. Pegfilgrastim was initiated in 351(56%) pts and filgrastim was initiated in 273 (44%) pts. Of the 624 pts, 120 (19%) received both pegfilgrastim and filgrastim (no pt used both products in the same cycle).
Neulasta (pegfilgrastim); Udenyca (pegfilgrastim-cbqv). Short-acting CSFs. Granix (tbo-filgrastim); Zarxio
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are